Silverback Therapeutics
3 clinical trials · Sponsor
◉ Watch Silverback Therapeutics
| Record | Firm | Date |
|---|---|---|
| A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors (NCT05234606) | Silverback Therapeutics | 2022-03-01 |
| A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers (NCT05091528) | Silverback Therapeutics | 2022-02-08 |
| A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors (NCT04460456) | Silverback Therapeutics | 2020-07-27 |
Track Silverback Therapeutics automatically
Every clearance here is in the API, with alerts when new ones post.